Journals / Interdisciplinary Medical Journal / 2022 / Cilt: 13 - Sayı: 45

The Importance of Procalcitonin Levels in COVID-19 Pneumonia

COVİD-19 Pnömonisinde Prokalsitonin Düzeylerinin Önemi

Pages
1–5
Publication Date
2022-04-07
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results show that the procalcitonin level cannot distinguish the presence of COVID-19 pneumonia in RT-PCR positive patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Our aim in this study is to determine how procalcitonin levels are affected in RT-PCR (Real-Time Polymerase Chain Reaction) positive COVID-19 pneumonia.
📊
Key Findings & Data:Methods: One hundred COVID-19 patients admitted to the hospital with positive RT-PCR test and above the age of 18 were included in our study.
💡
Conclusion & Impact:Conclusion: Our results show that the procalcitonin level cannot distinguish the presence of COVID-19 pneumonia in RT-PCR positive patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:COVID-19 · Pnömoni · Prokalsitonin

Abstract

Objective: Our aim in this study is to determine how procalcitonin levels are affected in RT-PCR (Real-Time Polymerase Chain Reaction) positive COVID-19 pneumonia. To investigate the value of this parameter in terms of biochemical parameters in RT-PCR positive patients and to propose new opinions on the subject. Methods: One hundred COVID-19 patients admitted to the hospital with positive RT-PCR test and above the age of 18 were included in our study. The data of the patients were collected retrospectively from the hospital system. RT-PCR positive patients were divided into two groups as thoracic CT (computed tomography) positive and CT negative, and procalcitonin values were investigated between these two groups. The obtained results were evaluated in the SPSS 25 program. Results: Of the 100 patients with positive RT-PCR tests, 39 patients were CT negative and 61 patients were CT positive. Although the procalcitonin levels measured in the CT positive patient group were higher than the CT negative group, it was not statistically significant (0.113 ± 0.154 ng / mL, 0.064 ± 0.058 ng / mL, p = 0.510). Conclusion: Our results show that the procalcitonin level cannot distinguish the presence of COVID-19 pneumonia in RT-PCR positive patients. High procalcitonin levels may predict that the disease becomes more complicated.

Özet

Amaç: Bu çalışmadaki amacımız, RT-PCR (Real-Time Polymerase Chain Reaction) pozitif COVID-19 pömonisinde prokalsitonin seviyelerinin nasıl etkilendiğini tespit etmek. Bu parametrenin RT-PCR pozitif hastalarda biyokimyasal parametre açısından değerini araştırmak, konuyla ilgili yeni görüşler ileri sürebilmektir. Gereç ve Yöntem: Çalışmamıza hastaneye başvuran 18 yaş üstü RT-PCR testi pozitif olup servise yatışı olan 100 COVİD-19 hasta dahil edildi. Hastaların verileri hastanenin sisteminden geriye dönük olarak toplandı. RT-PCR pozitif hastalar toraks BT (bilgisayarlı tomografi) pozitif ve BT negatif diye iki gruba ayrıldı ve bu iki grup arasında prokalsitonin değerleri araştırıldı. Elde elden sonuçlar SPSS 25 programında değerlendirildi. Bulgular: RT-PCR testi pozitif olan 100 hastanın 39'unda BT negatif, 61'inde BT pozitifti. BT pozitif hasta grubunda ölçülen prokalsitonin düzeyleri, BT negatif hasta grubuna göre yüksek olmasına rağmen istatiksel olarak anlamlı bulunmadı (0.113±0.154 ng/mL, 0.064±0.058 ng/mL, p=0.510). Sonuç: Elde ettiğimiz sonuçlar prokalsitonin düzeyinin RT-PCR pozitif hastalarda COVID-19 pnömonisinin varlığını ayırt edemeyeceğini göstermektedir. Prokalsitonin düzeyindeki yükseklik hastalığın daha komplike bir hale geldiğini öngörebilir.

🔖

Cite This Article

DEMİR, E., GİDEN, R., DEMİR, Z. (2022). The Importance of Procalcitonin Levels in COVID-19 Pneumonia. Interdisciplinary Medical Journal, Cilt: 13 - Sayı: 45, 1–5. https://ajindex.com/articles/887532

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Metintas S. Epidemiology of COVID-19. Eurasian J Pulmonol 2020;22, Suppl S1:2-7. T.C. Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü: COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi. Bilim Kurulu Çalışması, T.C. Sağlık Bakanlığı 12 Nisan 2020,
  2. Ankara.
  3. Nishiura, H.; Linton, N.M.; Akhmetzhanov, A.R. Initial Cluster of Novel Coronavirus (2019-nCoV) Infections in Wuhan, China Is Consistent with Substantial Human-to-Human Transmission. J. Clin. Med. 2020, 9, 488. https://doi.org/10.3390/jcm9020488. McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, clinical features, diagnosis, and prevention. UpToDate. (https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-epidemiology-virology-clinical-features-diagnosis-and-prevention).
  4. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;NEJMoa2002032. https://doi.org/10.1101/2020.02.06.20020974.
  5. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020;ciaa272. https://doi.org/10.1093/cid/ciaa272.
  6. Wang C, Horby P, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-473. https://doi.org/10.1016/S0140-6736(20)30185-9.
  7. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020. 27:25727. https://doi.org/10.1002/jmv.25727.
  8. Hao W, Li M. Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing. Travel Med Infect Dis. 2020; 34: 101627. https://doi.org/10.1016/j.tmaid.2020.101627.
  9. Wang S, Kang B, Ma, J, Zeng X, Xiao, M, Guo J, et al. A deep learning algorithm using CT images to screen for corona virus disease (COVID-19). medRxiv 2020.02.14.20023028. https://doi.org/10.1101/2020.02.14.20023028.
  10. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55(5): 105955. https://doi.org/10.1016/j.ijantimicag.2020.105955.
  11. Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe 2019; 15: 296-304. https://doi.org/10.1183/20734735.0258-2019.
  12. Carrol ED, Thomson APJ, Hart CA. Procalcitonin as a marker of sepsis. International Journal of Antimicrobial Agents 2002; 20: 1-9.
  13. Kamat IS, Ramachandran V, Eswaran H, G